Solventum Corporation SOLV
89.50
0.91
1.03%
as of 25 Sep
- Market cap
- $15.1B
- P/E
- 10.9×
Follow SOLV
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
Solventum Corporation (SOLV) Current ratio
Solventum Corporation's current ratio at the end of the quarter to 30 June 2026 was 1.0×, down 0.2× from fiscal 2025 (1.2×). That is below the Medical Instruments & Supplies industry median of 2.5× and below the Healthcare sector median of 3.0×.
Current ratio, annual
Annual
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 1.2× | 2.37% |
| FY2024 | 1.2× | (17.55%) |
| FY2023 | 1.5× | — |
Quarterly
| Period | Current ratio | Change |
|---|---|---|
| Jun 2026 | 1.0× | (4.62%) |
| Mar 2026 | 1.1× | (12.98%) |
| Dec 2025 | 1.2× | (17.97%) |
| Sep 2025 | 1.5× | 22.51% |
| 7 more quarters | Free account |
Current ratio against peers
| Company | Current ratio |
|---|---|
| RGEN Repligen Corporation compare | 9.1× |
| WST West Pharmaceutical Services, Inc. compare | 2.8× |
| ALC Alcon compare | 2.1× |
| BAX Baxter International Inc. compare | 1.9× |
| AVTR Avantor, Inc. compare | 1.8× |
| ATR AptarGroup, Inc. compare | 1.6× |
| ALGN Align Technology, Inc. compare | 1.4× |
| COO The Cooper Companies, Inc. compare | 1.2× |
| SOLV Solventum Corporation | 1.0× |
| Medical Instruments & Supplies industry median | 2.5× |
| Healthcare sector median | 3.0× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on SOLV
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement